|Bid||47.27 x 800|
|Ask||47.39 x 800|
|Day's Range||46.45 - 50.79|
|52 Week Range||12.71 - 56.40|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||51.81|
|Earnings Date||May 10, 2021 - May 14, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.36|
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027 (the "Convertible Notes"). The Convertible Notes are being offered in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company granted an option to the initial purchasers to purchase up to an additional $105 million aggregate principal amount of Convertible Notes.
Halozyme Therapeutics (NASDAQ: HALO) was well in double-digit territory on Wednesday, as its stock was up by over 14% in mid-afternoon trading. For its fourth quarter of 2020, Halozyme earned $121.7 million in revenue, more than double the $53.7 million of the year-ago quarter. Fueled by royalty payments that are expected to roughly double, revenue should come in at $375 million to $395 million for 2021 -- meaning at least a 40% improvement over the 2020 tally.
HALO earnings call for the period ending December 31, 2020.